Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fosaprepitant · Navitrux, L-758298

Small molecule · Antagonist of Substance P/neurokinin 1 receptor (TACR1) · developed by Avyxa Holdings

Approved FDA, Jun 2026
1 Registered trials

What is Fosaprepitant?

Fosaprepitant is a water-soluble prodrug that is converted to aprepitant after intravenous administration. Aprepitant selectively blocks substance P/neurokinin 1 receptors in the central nervous system, preventing substance P-induced emesis. It is studied in chemotherapy-induced nausea and vomiting.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Navitrux, L-758298
Drug type
Small molecule
Targets
Substance P/neurokinin 1 receptor (TACR1)
Mechanism
Antagonist of Substance P/neurokinin 1 receptor (TACR1)
Pathways
substance P signaling, emesis (central NK-1 receptor blockade)
Therapy area
Gastroenterology, Oncology
Developer
Avyxa Holdings
In trials of
HRTX
FDA status
Approved as Navitrux (June 24, 2026), NDA220436 · FDA label
UNII
6L8OF9XRDC

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02106494 Phase 3 Chemotherapy-induced Nausea and Vomiting Completed HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chemotherapy-induced Nausea and Vomiting

Other drugs acting on TACR1

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.